Comparison of validation protocols for blood pressure measuring devices in children and adolescents

Stella Stabouli¹*, Athanasia Chainoglou¹†, Kleo Evripidou¹, Carla Simão², Christina Antza³, Panagiotis Petrou⁴, Gilad Hamdani⁵, Javier Calpe⁶ and Empar Lurbe⁷

¹1st Department of Pediatrics, Faculty of Health Sciences, School of Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, ²Department of Pediatrics, Faculty of Medicine, Hospital Universitario de Santa Maria, FMUL, Lisbon, Portugal, ³3rd Department of Medicine, Faculty of Health Sciences, School of Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁴Pharmacoepidemiology-Pharmacovigilance, Pharmacy School, School of Sciences and Engineering, University of Nicosia, Nicosia, Cyprus, ⁵Nephrology and Hypertension Institute, Schneider Children’s Medical Center, Petah Tikva, Israel, ⁶Analog Devices, SLU, Paterna, Valencia, Spain, ⁷Department of Pediatrics, Centro de Investigación Biomédica en Red (CIBER) Fisiopatologia Obesidad y Nutricion, Instituto de Salud Carlos III, University of Valencia, Valencia, Spain

Accuracy of blood pressure (BP) measurement is important for the evaluation of hypertension in children and adolescents, and it is critically dependent upon the accuracy of the BP measuring device. A device that could pass validated protocols with reliable accuracy would be desirable in clinical and research settings. Several scientific organizations have published recommendations on the validation of different BP measuring devices. Most of them focus on adults but separate recommendations and validation criteria for BP devices intended for use in children and adolescents are included in some validation protocols. In this review, we compare the validation criteria for BP measuring devices among consensus documents from different scientific organizations focusing on the pediatric population and we discuss the evidence gaps targeting the needs for validated BP measuring devices in children and adolescents. We also highlight common pitfalls in the validation studies of BP measuring devices in children and adolescents using the example of office BP devices.

KEYWORDS
blood pressure, device, validation, children, adolescents
Introduction

Accuracy of blood pressure (BP) measurement is important for the evaluation of hypertension in children and adolescents, and it is critically dependent upon the accuracy of the BP measuring device. The need for evaluation of the accuracy of automated BP measuring devices available in the market, both for use in clinical settings, as well as out-of-office environment, using validation procedures has been well-recognized by the scientific community and the manufacturers (1). A device that can pass validated protocols with reliable accuracy would be desirable in clinical and research settings.

Several scientific organizations have published consensus documents on the validation of BP measuring devices. First, in 1987, the American Association for the Advancement of Medical Instrumentation (AAMI) published a monograph on clinical validation procedures for automated BP monitors, which was recognized as a national standard in the United States (2). This protocol was subsequently revised in 1992 and 2002. In 1990, the British Hypertension Society (BHS) published another validation protocol for BP monitors, which was revised in 1993 (3, 4). The German Hypertension League (DHL) developed its own Quality Seal Protocol in 1999 (5), and in 2002, the European Society of Hypertension (ESH) introduced the ESH-International Protocol (ESH-IP) that was revised in 2010 (ESH-IP2) (6, 7). In 2009, the International Organization for Standardization (ISO) published its own protocol (8) and in 2013 the American National Standards Institute (ANSI), the AAMI, and the ISO collaboratively released a revised protocol (9). Finally, in 2018, the AAMI/ESH/ISO released the most recent validation protocol in an effort to develop a single universal protocol for the validation of BP monitors (10).

Most of the validation protocols are developed only for adults and children are regarded as a special population requiring separate validation studies. The main objective of these consensus statements was to provide practical guidance for validation studies of BP measuring devices and to ensure that conditions are fulfilled, and data are reported in detail. Still, despite previous and current recommendations performing and reporting on validation studies present significant limitations. The pitfalls are more pronounced when the validation studies are performed in children and adolescents (11).

In this review, we compared the validation criteria for BP measuring devices among the consensus documents from scientific organizations focusing on the pediatric population and we discuss the gaps in evidence targeting the needs for validated BP devices in children and adolescents. We also highlight common pitfalls in the validation studies of BP measuring devices in children and adolescents using the example of office BP devices.

Differences between validation protocols

The basic differences between the validation protocols are summarized in Table 1 and include the following key features:

Sample size

A major difference between protocols is that the ESH-IP2 is the only one that requires a smaller sample size of 33 individuals instead of 85 and 96 individuals that the other protocols require.

Age of participants

Most of the protocols are designed for adults, whereas the ANSI/AAMI/ISO and the AAMI/ESH/ISO include children older than 12 years.

Distribution of participants

In all protocols, the inclusion criteria for the participants vary in regard to their age, sex, arm circumference, and entry BP distribution. The sample is distributed based on age only in DHL, whereas in the others the distribution is random. Most of the protocols, except from the BHS, include participants selected with sex criteria. Only the ANSI/AAMI/ISO and AAMI/ESH/ISO protocols use sample that is selected according to the arm circumference. Finally, all protocols use BP range as a criterion for the selection of the subjects.

Measurement method

All protocols endorse the same-arm sequential measurement as the most accurate method except for the ANSI/AAMI/ISO, which suggest alternatively the same or the opposite arm simultaneous BP measurement procedure.

Reference blood pressure measuring device

In the BHS, DHL, and ESH protocols, the recommended reference BP measurement device is a mercury sphygmomanometer, whereas the protocols of ANSI/AAMI/ISO and AAMI/ESH/ISO suggest alternatively the use of other non-mercury devices with a maximum error of 1 mmHg.
### TABLE 1 Comparison of validation protocols for blood pressure (BP) measuring devices.

| Organization | BHS (3) | Quality seal protocol -DHL (4) | ESH IP2 (5) | ANSI/AAMI/ISO (7) | AAMI/ESH/ISO (8) |
|--------------|---------|--------------------------------|-------------|--------------------|------------------|
|              | British Hypertension Society | German Hypertension League | European Society of Hypertension | American National Standards Institute/Association for the Advancement of Medical Instrumentation/International Organization for Standardization Collaboration | Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization Collaboration |
| Last revision | 1993 | 1999 | 2010 | 2013 | 2018 |
| Sample size | 85 | 96 | 33 | ≥85 | ≥85 |
| Participants’ age | 15–80 years | > 20 years | ≥25 years | > 12 years | > 12 years |
| Age distribution | By chance | 3 age groups Distribution based on age and SBP and DBP levels | By chance | By chance | By chance |
| Sex distribution | By chance | Equally represented | ≥10 subjects of each sex | ≥30% of each sex | ≥30% of each sex |
| Arm circumference distribution | By chance | By chance | Single cuff: ≥40% in the upper/lower half of the specified cuff-range ≥20% in the upper/lower quarter. Multiple (n) cuffs: each cuff at least 1/(2 × n) of the subjects | Single cuff: ≥40% in the upper/lower half of the specified cuff-range ≥20% in the upper/lower quarter. Multiple (n) cuffs: each cuff at least 1/(2 × n) of the subjects |
| BP range distribution | SBP (mmHg): 20–40 years ≥90: ≥8 subjects, 90–120: ≥20, 130–160: ≥20, 161–180: ≥20, > 180: ≥8; DBP (mmHg): <60: ≥8 subjects, 60–79: ≥20, 80–100: ≥20, 101–110: ≥20, > 110: ≥8 | SBP (mmHg): 140–12–12 subjects, 130–160:10–12, ≥160 mmHg: 10–12 DBP (mmHg): ≤80–10–12, 80–100:10–12, > 100:10–12 | SBP (mmHg): ≤100 mmHg: ≥5% of readings ≥140 mmHg: ≥20% ≥160: ≥5% DBP (mmHg): ≤60 mmHg: ≥5% ≥85 mmHg: ≥20% ≥100 mmHg: ≥5% | SBP (mmHg): ≤100 mmHg: ≥5% of readings ≥140 mmHg: ≥20% ≥160: ≥5%, DBP (mmHg): ≤60 mmHg: ≥5% ≥85 mmHg: ≥20% ≥100 mmHg: ≥5% |
| Reference BP measurement | Mercury sphygmomanometer | Mercury sphygmomanometer | Mercury sphygmomanometer | Mercury sphygmomanometers or non-mercury auscultatory device with maximum error ≤ 1 mmHg | Mercury sphygmomanometers or accurate non-mercury devices with maximum error ≤ 1 mmHg |
| Measurement method | Same arm sequential BP measurement | Same arm sequential BP measurement | Same arm sequential BP measurement | Same arm sequential or simultaneous (same or opposite arm) BP measurement | Same arm sequential BP measurement |
| Paired BP measurements | 255 | ≥288 | 99 (22–44 in each BP range) | 255 | 255 |
| Specific guidelines for ABPM | Yes | No | No | Yes (separate validation protocols) | Yes (separate validation protocols) |

(Continued)
| BHS (3) | Quality seal protocol - DHL (4) | ESH IP2 (5) | ANSI/AAMI/ISO (7) | AAMI/ESH/ISO (8) |
|---------|--------------------------------|-------------|-------------------|------------------|
| **Pass criteria** | Criteria based on mean difference and SD and point system for individual paired SBP and DBP readings. Pass if the device fulfills all the following criteria: mean difference for SBP and DBP ≤ 5 mmHg and the SD ≤ 8 mmHg and point score ≥ 55% of the maximum attainable point score. | Criteria based on the number of readings with test-reference BP difference ≤ 5, 10, 15 mmHg. Criteria for individual BP measurements (Part 1) individual subjects (Part 2) Part 1: Pass if 73.7% (73/99) of differences between readings: ≤ 5 mmHg, 87.9% (87/99) ≤ 10 mmHg, 97.6% (96/99) ≤ 15 mmHg Part 2 (Accuracy): number of subjects with 0, 2 or 3 of absolute difference ≤ 5 mmHg | Criteria based on mean BP differences and their SDs. Criteria for individual BP readings and individual subjects. Criteria 1 and 2 should be applied for SBP and DBP. Criterion 1 (for individual BP readings): The mean BP difference ≤ 5 mmHg and SD ≤ 8 mmHg. Criterion 2 (for individual subjects): The mean difference and SD of BP readings within threshold defined by mean value of criterion 1. | Criteria based on mean BP differences (test vs. reference) and their SDs. Criteria for individual BP readings and individual subjects. Criteria 1 and 2 should be applied for SBP and DBP. Criterion 1 (for individual BP readings): The mean BP difference ≤ 5 mmHg and SD ≤ 8 mmHg. Criterion 2 (for individual subjects): The mean difference and SD of averaged BP differences must be within a threshold defined by mean value of criterion 1. Additionally, the number of absolute BP differences within 5, 10, and 15 mmHg (ESH-IP2) and standardized Bland–Altman scatterplots will be presented. The mean test-reference BP difference and SD per cuff subgroup must be reported without pass/fail criteria for the test device. Children < 3 years, pregnancy including pre-eclampsia, arm circumference > 42 cm, atrial fibrillation Possible special groups: individuals aged 12–21 or > 80 years and those with end-stage kidney disease. Special population studies with smaller sample sizes should be performed only after a full general population study has been successfully completed. If the device is intended only for a special population, then a full 85-subject study is required. |
| **Special groups** | Pregnant women, elderly, and children. Only if a device has successfully completed all phases of Part I and has achieved at least a B grading for accuracy for both SBP, DBP (Part II.I) | Pregnant women, diabetics, arm circumference > 33 cm | No specific guidelines Separate studies recommended for special populations | Pregnant women, neonates and children, heart irregularities/disease |
| **Special occasions** | During exercise and in various postures. Only if a device has successfully completed all phases of Part I and has achieved at least a B grading for accuracy for both SBP, DBP (Part II.I) | No specific guidelines | No specific guidelines | During exercise |
| **Extra** | Examines intradevice variability, accuracy of devices after long term period of performance | |

BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; ABPM, ambulatory blood pressure monitoring; SD, standard deviation.
Pass/Fail criteria

Different pass criteria have been used in all the protocols. The DHL, AANSI/AAMI/ISO, and AAMI/ESH/ISO criteria are based on calculating the mean difference and the standard deviation (SD) between the test and the reference BP measuring devices. The DHL has used additionally a point system scoring. On the other hand, the BHS and the ESH-IP2 criteria are based on summing up the cumulative incidence of the difference between the test and the reference BP devices in the categories of less than 5, 10, and 15 mmHg.

Specific guidelines for ABPM

Only the BHS, ANSI/AAMI/ISO and the AAMI/ESH/ISO protocols highlight the need of separate validation studies for ABPM.

Special occasions (such as exercise)

The BHS includes specific guidelines for the validation of BP devices in special occasions, such as during exercise and in different postures, whereas the AAMI provides recommendations for the validation of BP monitors only during exercise.

Special populations (such as pregnant women, children, elderly, and patients with diabetes)

All the protocols recognize that BP devices should be validated in special populations and provided specific recommendations for these groups except for ESH-IP2 that recommends separate studies to be carried out.

Finally, the BHS protocol is the only one that tests the intradevice variability and the consistency in the performance of the BP monitor after prolonged use.

Validation protocols in children and adolescents

The recommendations for validation of BP measurement devices are mainly "tailor made" for adults. Although some organizations have addressed the validation in special populations including children, they mostly consider children as "small adults" and do not take into account several distinct characteristics of the pediatric population. Finally, most of the documents on the validation of BP measuring devices have included in the writing committees only adult hypertension specialists putting less emphasis on this special population. Given that the scientific evidence beyond the recommendations is limited and all organizations provide consensus documents the lack of statements on the validation of BP measuring devices specifically addressing to the unique characteristics and needs of children and adolescents by specialists and practitioners caring exclusively for pediatric patients gains extreme importance as a fundamental step for accurate and reliable BP measuring devices in the pediatric population.

The BHS, ANSI/AMI/ISO, and AAMI/ESH/ISO are the only protocols, which include specific recommendations for the validation of BP measuring devices in children (3, 9, 10) (Table 2). According to BHS, a sample of 30 children aged 5–15 years with specific inclusion criteria for their age, sex, and entry BP distribution is required (3). Afterwards, the mean BP difference and SD between test and reference device measurements should be reported without specified pass criteria. The ANSI/AMI/ISO and AAMI/ESH/ISO protocols share the same principles (9, 10). If the device is intended for use on both adults and children, the sample should consist of 35 children aged 3–12 years and 50 individuals aged older than 12 years. On the other hand, if the device is intended only for the use on children, a study with a sample of 85 children with specific criteria for sex and cuff size distribution should be carried out. According to the protocols, the studies should meet both two criteria for BP differences of individual readings and of individual subjects. The criterion 1 defines that the mean BP difference (test minus reference BP for all of the measurements) must be 5 mmHg or less, and its SD 8 mmHg or less for systolic and diastolic BP and the criterion 2 that the SD of averaged BP differences (test minus reference BP per subject) must be within a threshold defined by the mean of criterion 1 (9).

Considerations on validation protocols in children and adolescents

Population and sample size

The optimal sample size for a BP measuring device validation study varies among different organizations. As mentioned above the ESH validation protocol suggested a minimum of 33 subjects, while the BHS, the ANSI/AAMI/ISO as well as the AAMI/ESH/ISO required 85 participants (3, 10). The disagreement on ideal population sample sizes lies on the statistical power of the validation procedure against the cost and complexity (10, 12).

In the AAMI/ESH/ISO consensus statement, it was reported that that a validation study with a sample size of 35 subjects would be inadequate for a moderate accuracy device defined as a difference of 4 ± 5 mmHg compared to the test device, because of an unacceptably high at 28% chance to fail (10). However, according to a biostatistician report, a validation study with 35
### TABLE 2 Comparison of validation protocols for BP measuring devices in children.

| BHS revised (1993) (3) | ANSI/AAMI/ISO (2013) (7) | AAMI/ESH/ISO (2018) (8) |
|------------------------|--------------------------|-------------------------|
| Age range              |                          |                          |
| 0–5 years              | 5–15 years               | 3–12 years              |
| 3–12 years             | 85 subjects              | 3–12 years              |
| Age distribution       |                          |                          |
| 0–12 months:           | 30 subjects              | 35 subjects             |
| 15 subjects,           | 30 subjects              | 85 subjects             |
| 1–5 years: 15          | Evenly distributed       | Not specified           |
| 5                      | 85 subjects              | 85 subjects             |
| Sex distribution       |                          |                          |
| ≥10 each of sex        | By chance                | ≥30% of each sex        |
| BP range distribution  |                          | Not specified           |
| SBP:                   |                          | As the total 85-subject study |
| DBP:                   |                          | Without BP distribution requirements |
| Arm circumference      | Not specified            |                          |
| distribution           | 5/30 > 70th centile for weight | 40% of subjects’ circumference within upper half of range; 40% within lower half; 20% of subjects’ circumference within upper quarter of range; 20% within lower quarter. N cuffs, test each in ≥ 1/(2 × n) subjects |
|                        | 5/30 < 30th centile for weight | 40% of subjects’ circumference within upper half of range; 40% within lower half; 20% of subjects’ circumference within upper quarter of range; 20% within lower quarter. N cuffs, test each in ≥ 1/(2 × n) subjects |

(Continued)
| Reference BP measurement device | BHS revised (1993) (3) | ANSI/AAMI/ISO (2013) (7) | AAMI/ESH/ISO (2018) (8) |
|---------------------------------|------------------------|--------------------------|-------------------------|
| Conventional mercury sphygmomanometry | **Mercury sphygmomanometer, or non-mercury auscultatory device with max permissible error ± 1 mmHg** | **Mercury sphygmomanometer, or non-mercury auscultatory device with max permissible error ± 1 mmHg** | **No pass threshold is provided** |
| Reference diastolic BP Pass criteria | K5 Mean difference and SD for test-reference BP differences to be reported No pass threshold is provided | K4 Criterion 1: mean ± SD for test-reference BP differences ≤ 5 ± 8 mmHg Criterion 2: intersubject SD of BP differences within threshold defined by the mean of criterion 1 | K4 Mean difference and SD of SBP and DBP should be reported separately for subgroups aged 3–12 and > 12 years Pass criteria: validation criteria 1 and 2 Criterion 1: mean ± SD for test-reference BP differences ≤ 5 ± 8 mmHg Criterion 2: intersubject SD of BP differences within threshold defined by the mean of criterion 1 |

BP: blood pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure, SD: standard deviation.
subjects would be adequate for high- or low-accuracy devices. Then, it was calculated that a population sample of 85 subjects as previously suggested by the ANSI/AAMI/ISO has an acceptable chance of failing (18%) supporting the previous consensus of at least 85 subjects and taking into account that most devices in the market probably have moderate accuracy.

Adolescents older than 12 years are considered as general population and are evaluated within an 85-population sample. Transfer functions and in-built algorithms for the calculation of systolic and diastolic BP are not usually available by the manufacturer (13). The algorithms differ between devices, are considered proprietary for the manufacturer, and are, therefore, confidential. Of note, these algorithms are developed for adults with higher BP levels, and automated initial cuff inflations to high pressures may cause discomfort or pain in the child precluding its cooperation (14). Oscillation may also be lower in the youngest with lower BPs. For example, for a 12-year-old boy with short stature at the 5th centile, the median level (50th centile) of systolic and diastolic BP is at 101/65 mmHg, respectively. Then, it is well described that in adolescents, the pulse wave contour is different than in older individuals with stiffer arteries (15). Whether these algorithms could evaluate with the same accuracy, the BP level in an adolescent as young as 12 years old and in a 65-year-old individual remains unanswered and uninvestigated.

A low-accuracy device for adolescents with an in-built algorithm resulting in high accuracy in older subjects would result in a medium-accuracy device with the inclusion of subjects 12–18 years in general population study. While the impact of this result would be moderate for the adult population, it may have important implications for adolescents regarding misclassification of their BP status and possibly undiagnosed hypertension.

The ESH 2016 guidelines on the management of high BP in children and adolescents consider that only older adolescents (≥16 years) are evaluated for hypertension using the adult BP threshold (16). It may be prudent that this age limit of 16 years would also apply for the validation studies in the general population. Then, a separate validation study considering adolescents <16 years as a special population may offer the opportunity for more precise assessment of accuracy before a device is suggested in the adolescent age range.

Children are considered as a special population if younger than 12 years. According to the BHS, the number of pediatric patients 3–12 years needed for a BP measurement device validation study is 30, if the device has been successfully validated in the general population. The ANSI/AAMI/ISO and the AAMI/ESH/ISO recommend a sample size of at least 85 subjects if the study includes only children, but in the case of an existent validation study for the general population, the required sample size is 35 children. For validation, studies including both children and adults’ general population, a total sample size of at least 85 is required, with children consisting of 35 out of 85 participants. The same concerns about the transfer functions and in-built algorithms may apply for children 3–12 years. Again, given all the above considerations, it is unclear if the sample of 35 children would be adequate for this age range with low oscillation and different vascular functions for moderate accuracy devices (13).

### Cuff size

Most monitors included two cuffs for the adult population. Special-size cuffs are not always available and in case of minors, children, and adolescents, this is an important issue. In the same concept as in the previous section, younger adolescents may erroneously be considered as general populations as they have different characteristics. It is recommended that the cuffs used for reference auscultatory BP measurement must have an inflatable bladder length that covers 75–100% of the upper arm circumference of each participant and a width that covers 37–50% of the arm circumference measured at the upper arm midpoint between acromion and olecranon (10). Many manufacturers include adult cuffs that are suitable for arm length >22 cm. For 12–15–years-old girls, the 5th–25th centile of midarm circumference is <20 cm and adult cuffs are not suitable for reliable BP measurement (17, 18). Similarly, the 25th centile of midarm circumference of a 12-year-old boy is <20 cm and for 14- and 15-years-old boys is at 22 and 23 cm, respectively. In the AAMI/ESH/ISO, it is recommended that inflatable bladder dimensions should be 12 cm for 12–15 years old and 15 cm for 15–18 years old.

If a device is considered for validation in children and adolescents, commercially available cuffs sizes both for the validation study but also for routine use should be a prerequisite criterion. Although not specifically reported in the consensus documents using cuffs from other manufacturers or from the test device, not designed for the device under evaluation, for the reference BP measurement during the validation study may result in significant measurement errors and significant bias of the validation study methodology.

### Diastolic blood pressure

The latest ESH and American Academy Pediatrics (AAP) guidelines for the diagnosis of high BP in children and adolescents recommend the use of Korotkoff sound 5 (K5) during office BP measurement (16, 19). The most frequently used validation protocol, the ANSI/AAMI/ISO recommends the use of Korotkoff sound 4 (K4) during the validation procedure which constitutes a major inconsistency between validation and clinical use of a device (9). However, in line with the guidelines for diagnosis of the hypertension in children and adolescents, the BHS, as well as the universal AAMI/ESH/ISO 2018 protocol recommend the use of K5 (3, 20). The latter recommends that if K5 is not audible, the child should be excluded.

### Validation criteria

In all consensus validation documents, two criteria as defined by the ANSI/AAMI/ISO are used to evaluate the
TABLE 3  Validated devices for office BP measurement in children and adolescents.

| Device (References) | No. of patients/age range | No. of pediatric patients/age range | Validation protocol | Result | Test device | DBP definition (K4 or K5) | Cuff sizes used | Device commercially available cuff sizes | Funding |
|--------------------|--------------------------|------------------------------------|---------------------|--------|-------------|--------------------------|----------------|-------------------------------------------|---------|
| BpTru BPM-100      | 36/3–18 years            | 36/36 (3–18 years)                 | ANSI/AAMI, BHS      | Pass, grade A | Auscultatory mercury sphygmomanometer | K5 na          | Child 13–18 cm, Small adult 18–26 cm, Regular adult 26–34 cm, Large adult 32–43 cm, Extra–Large adult 41–52 cm | nr      |
| CasMed 740         | 29/< 3 years             | 29/29 (29 days–1 year: 5, 1–3 years: 3) | ANSI/AAMI/ISO       | Pass    | Invasive arterial measurement | na Neonate cuffs: #1: 3–6 cm #2: 4–8 cm #3: 6–11 cm #4: 7–14 cm Child cuff: 13–20 cm | Neonate: #1: 3–6 cm #2: 4–8 cm #3: 6–11 cm #4: 7–14 cm | CAS Medical Systems Inc. |
| Datascope Accutorr Plus | 44/5–15 years          | 44/44 (5–15 years)                | ESH                 | Pass    | Auscultatory mercury sphygmomanometer | K5 na          | 9–14.8 cm orange, 13.8–21.5 cm green, 20.5–28.5 cm light blue, 27.5–36.5 cm navy blue, 35.5–46 cm burgundy, 45–56.5 cm brown | Hong Kong Paediatric Nephrology Society, Children’s Kidney Trust Fund |
| Dinamap Procare-120 | 44/5–15 years           | 44/44 (5–15 years)                | ESH                 | pass/fail | Auscultatory mercury sphygmomanometer | K5 na          | Infant, Child, Small adult, Adult, Large adult, Adult thigh | Hong Kong Paediatric Nephrology Society, Children’s Kidney Trust Fund |
| Dinamap Procare-200 | 45/(7–18 years)         | 45/45 (7–18 years)                | BHS, ESH            | pass, pass/fail | Baumanometer Mercury Gravity Sphygmomanometer (W.A. Baum Co., Copiague, NY, USA) | na Child 17–22 cm, Small adult 22–30 cm, Large adult 30–38 cm | Neonate #1 Neo #2 Neo #3 Neo #4 Neo #5 Infant, Child, Small adult, Adult, Large adult, Adult thigh, Adult long cuff (Different assortment packs available) | Korea Center for Disease and Prevention (KCDC) |

(Continued)
### TABLE 3 (Continued)

| Device (References) | No. of patients/age range | No. of pediatric patients/age range | Validation protocol | Result | Test device | DBP definition (K4 or K5) | Cuff sizes used | Device commercially available cuff sizes | Funding |
|---------------------|---------------------------|-------------------------------------|---------------------|--------|-------------|--------------------------|----------------|--------------------------------------|---------|
| **Successful validation including only children** |
| Raycome RBP-1200 (Shenzhen Raycome Health Technology, China) | 3–12 years | 87/87 (3–12 years) | ANSI/AAMI/ISO | Pass | Auscultatory mercury sphygmomanometer | K5 | Extra small 15–18 cm, small 18–22 cm, standard 23–32 cm | Extra small (SS) 15–18 cm, Small (S) 18–22 cm | National Nature Science Foundation of China, Shenzhen Raycom Health Technology Company (Shenzhen, China) |
| CAS 9010 (CAS Medical Systems, Branford, Connecticut, USA) | 4–78 years | 35/88 | AAMI | Pass | Auscultatory mercury sphygmomanometer | na | na | na | Nippon Colin (Komaki, Japan) and Colin Medical Instruments (San Antonio, TX) |
| Colin BP8800MS (Colin Medical Instruments Corp., San Antonio, TX) | 170, 8 months–80 years | 85/170 (8 months–16 years) | ANSI/AAMI | Pass | Mercury manometer (model Marshall Deluxe, Omron Healthcare, Inc., Vernon Hills, IL) | K5 | Infant 8–12.5 cm, Child 12.5–18 cm, Small adult 18–24 cm, Adult 24–32 cm, Large adult 32–40 cm | Neonate #1, #5, Infant, Child, Small adult, Adult, Large adult | Microlife, Widnau Switzerland, University of Athens Special Account for Research Grants |
| Fukuda Denshi DS-7000/NIBP-701 (Fukuda Denshi Co., Tokyo, Japan) | 119/42.2 ± 21.0 years | 33/119 (15 pediatric (3–12), 18 neonate/infant (< 3)) | ANSE/AAMI, BHS | Pass, pass-grade A | Intraarterial-neonates and infants, auscultatory-children and adults | na | na | Infant cuff, Child cuff, Large/Regular/Small Adult cuff | Fukuda Denshi |
| Microlife WatchBP Office (Microlife AG, Widnau, Switzerland) | 88/3–70 years | 37/88 (3–12 years) | ANSI/AAMI/ISO | Pass | Auscultatory mercury sphygmomanometer (Baumanometer, WA Baum Co., Inc., New York, New York, USA) | K5 | Small 14–22 cm, Medium 22–32 cm, Large 32–42 cm | Medium 22–32 cm, Large 32–42 cm | Microlife, Widnau Switzerland, University of Athens Special Account for Research Grants |
| Midmark IQvitals Zone (Midmark Corporation, USA) | 85/3–77 years | 35/85 (7–17 years) | ANSI/AAMI/ISO | Pass | Manual auscultation | K5 | na | Child, Small adult, Adult, Adult long, Large adult, Large adult long, Thigh | Midmark Corporation |
| Nihon Kohden PVM-2701/Impluse-1 (32) | 110/na (<12 years) | 41/110 (<12 years) | ANSI/AAMI/ISO | Pass | Auscultatory mercury sphygmomanometer | K4 | na | Infants 8–13 cm, Children: Small 12–18 cm Standard 15–23 cm, Adults: Standard 21–30 cm, Large adult 33–45 cm, Thigh 33–45 cm | University of Tennessee Clinical Research Center and the Tennessee Clinical Trials Network, Nihon Kohden |
| Omron HBP-1300 (Omron Healthcare Co., Kyoto, Japan) | 85/4–72 years | 35/85 (<12 years) | ANSI/AAMI/ISO | Pass | Auscultatory mercury sphygmomanometer | K4 | SS 12–18 cm, S 17–22 cm, M 22–32 cm, L 32–42 cm, XL 42–50 cm | SS 12–18 cm, S 17–22 cm, M 22–32 cm, L 32–42 cm, XL 42–50 cm, | Guangzhou Boji Medical Biotechnological Co. Ltd. |

(Continued)
### TABLE 3 (Continued)

| Device (References) | No. of patients/age range | No. of pediatric patients/age range | Validation protocol | Result | Test device | DBP definition (K4 or K5) | Cuff sizes used | Device commercially available cuff sizes | Funding |
|---------------------|---------------------------|------------------------------------|---------------------|--------|-------------|--------------------------|----------------|-------------------------------------------|---------|
| Omron HBP-1320 (Omron Healthcare Co., Kyoto, Japan) (34) | 88/4–70 years | 38/88 (4–12 years) | ANSI/AAMI/ISO | pass, pass | Auscultatory mercury sphygmomanometer | K5 | SS 12 to 18 cm, S 17 to 22 cm, M 22 to 32 cm, L 32 to 42 cm, XL 42 to 50 cm | SS 12–18 cm, S 17–22 cm, M 22–32 cm, L 32–42 cm, XL 42–50 cm | nr | OMRON (Japan) |
| Omron M3500 (Omron Healthcare Co., Kyoto, Japan) (35) | 135/≥3 years | 35/135 (3–12 years) | ANSI/AAMI/ISO | Pass | Auscultatory mercury sphygmomanometer | K4 and K5 | Super small: 12–18 cm, Small: 17–22 cm, Standard: 22–32 cm, Large: 32–42 cm, Xlarge: >42 cm | Standard IEC adult cuff or GS cuff | Optional IEC adult oversized cuff | IE3 children cuff (9 cm, 7 cm), Adult cuff (S, M, L, XL), GS cuff (SS, S, L, XL) |
| Welch Allyn Pro BP 2000 (Welch Allyn, Skaneateles Falls, New York, USA) (36) | 88/ ≥3 years | 35/88 (3–12 years) | ANSI/AAMI/ISO | Pass | Auscultatory mercury sphygmomanometer | K4 | Child 15–21 cm, Small adult 20–26 cm, Adult 25–34 cm, Adult long 32–43 cm, Adult large Long 32–43 cm, Thigh 40–55 cm | Child 15–21 cm, Small adult 20–26 cm, Adult 25–34 cm, Adult long 32–43 cm, Adult large long 32–43 cm, Thigh 40–55 cm | Welch Allyn |
| Welch Allyn ProBP 3400 (Welch-Allyn Medical Products, New York, USA) (37) | 111, ≥3 years | 14/111 (3–12 years) | ANSI/AAMI, BHS | pass, grade A | Auscultatory mercury sphygmomanometer | K5 | na | Small child (12 cm) to thigh (35 cm) | nr |
| Welch Allyn SureBP, StepBP (Welch-Allyn Medical Products, New York, USA) (38) | 102/ ≥3 years | 15/102 (3–12 years) | ANSI/AAMI, BHS | Pass, grade A | Auscultatory mercury sphygmomanometer | K5 | na | Extra small 15–24 cm, Standard wide 22–42 cm, Extra large 40–54 cm | nr |
| Welch-Allyn Spot Vital Signs (Welch-Allyn Medical Products, New York, USA) (39) | 5–77 years, 47 ± 16 | na, > 5 years | ANSI/AAMI | Pass | Auscultatory mercury sphygmomanometer | (Tycos brand sphygmomanometer; Tycos, Inc., Arden, North Carolina, USA) | K5 | na | Neonate: #1: 3.3–5.6 cm #2: 4.2–7.1 cm #3: 5.4–9.1 cm #4: 6.9–11.7 cm #5: 8.9–15 cm, Infant 9.8–13.3 cm, Small child 12.4–16.8 cm, Child 15.8–21.3 cm, Small adult 20–27 cm, Adult 25–34 cm, Adult large 32–43 cm, Large 32–43 cm, Thigh 40–55 cm | Welch Allyn, Inc. |
| YuWell YE9000 (Jiangsu Yu Yue Medical Equipment and Supply, China) (26) | 85/3–12 years | 35/85 (4–11 years) | ANSI/AAMI/ESH/ISO | Pass | Auscultatory mercury sphygmomanometer (YuYue, Jiangsu Province, China) | K5 | 18–22 cm (small), 22–32 cm (medium), and 32–42 cm (large) | na | YuYue Medical Equipment & Supply Co., Ltd. |

DBP, diastolic blood pressure; na, not available; nr, not reported.
Successful validation of devices usually reported as pass or fail in review articles (9). The same criteria apply for pediatric studies although no studies have been performed to evaluate the suitability of these criteria in pediatric patients. However, only criterion 1 is necessary to be reported in the case of 35 subject studies. Of note, in case of a validation study including children in a general population study, both criteria should be reported separately for the pediatric subgroup.

The example of validated office blood pressure devices in children and adolescents

A systematic search using Medline from inception to May 30, 2022, was performed to identify studies validating the accuracy of office BP monitors in the pediatric population alone or as a subgroup of the study population. We used the following search terms: (Office) AND (Blood Pressure) AND (Validation) AND (Monitor) OR (Device) AND (Children) OR (Adolescents). A hand-searching was also conducted for eligible studies. The reference list of each article included was checked for extra bibliography. Duplicates were removed. We included studies in the English language only. Two independent reviewers (KE and CS) screened titles and abstracts for eligible studies. The reference list of each article included was checked for extra bibliography. Duplicates were removed. We included studies in the English language only. Two independent reviewers (KE and CS) screened titles and abstracts for eligible studies. Differences between the two reviewers regarding study eligibility were resolved by a third reviewer (SS). Finally, study and population characteristics were extracted from each included study.

The search resulted in 21 studies with successful validation in children and adolescents (Supplementary Figure 1) (21–39). Validated devices for office BP measurement, children and adolescents using different available validation protocols are presented in Table 3. The accuracy of BP measuring devices was assessed using the ANSI/AAMI and the ANSI/AAMI/ISO protocol in almost 80% of the validation studies in children and adolescents (Figure 1). About half of the studies were performed before 2010. Few office BP devices were validated based on two different protocols, both the ANSI/AAMI and the BHS protocols (n = 4) (21, 29, 37, 38) or the BHS and the ESH-IP (n = 2) (23, 24, 39). In all studies, devices passed the validation criteria by both protocols for systolic and diastolic BP with the exception of the Dinamap Procare-200 device that failed for the diastolic BP with ESH protocol criteria (24). One device that has been assessed by two studies was evaluated as passed in one of them but failed in the other one (23, 39). In one study, 3 devices were evaluated simultaneously (23).

Only 6 out of 7 studies that included exclusively pediatric population fulfilled the pass criteria. Three used the ESH-IP protocol (23, 24), which is not designed for children, two the BHS protocol, and three the ANSI/AAMI/ISO protocol. Among studies that used the ANSI/AAMI/ISO protocol, two had an inadequate sample size, leaving only 1 study that used the ANSI/AAMI/ISO protocol to provide the best available validation evidence for office BP devices in children (25).

The test device used in almost all studies was a mercury sphygmomanometer measuring BP by the auscultatory method. Intra-arterial measurement as a test method was used in 2 studies (22, 29), one of them including only neonates and infants (29). Most studies included two trained observers for the BP measurements as recommended and most of them were health professionals.

Seven out of twenty-one validating studies did not meet the criteria for the age range required based on the selected protocols. None of the studies reported the required age distribution in the population. Only five studies met both the sample age and sample size required for a validation study. Although the available protocols do not specify the required ratio of female–male participants for children's studies, most of the studies that defined their population, recruited the same percentage of patients of each sex.
Among studies that used the AAMI protocol the one that included 85 children reported both validation criteria 1 and 2. Also in studies including both the general population and children both validation criteria 1 and 2 were used. In the studies including 35 children with an existent validation study for adults, only criterion 1 was used. Funding by the industry was reported in eight studies (25, 28–33, 35, 36).

Pitfalls during validation procedure

Several validation studies in children or including children in the general population lack adequate reporting of validation data according to validation recommendations or not fulfill all requirements (Table 3). Common pitfalls include:

Sample size

The requirements for sample size were satisfied in 12 out of 21 studies. For example, the validation study by Alpert et al., using the ANSI/AAMI/ISO protocol included only children, but the sample size was less than the required sample size of at least 85 subjects (36). The same number of subjects was included by Mattu et al. (21) in a validation study for a BP measuring device intended for use in children but considered adequate as there was already an existent validation study for the general population (21).

Cuff size

In about half of the studies, no data were reported regarding the cuffs used for the validation procedure. Moreover, in several cases, information about commercially available cuffs for the validated device was not reported in manufacturer's sites. Manufacturers may provide only one adult cuffs with the device and pediatric cuff sizes are usually sold separately as extra accessories. In the validation studies that included both children and adults, 6 out of 13 studies used for the validation procedure the cuffs provided by the manufacturer along with the device (Table 3). Cuff sizes used during the validation with the description of cuffs' length and width were usually reported, but only 4 of them reported the number of subjects tested for different cuff sizes. In the validation studies that included only children, 2 out of 6 studies used the same size cuffs as provided for the validation, and only 3 out of 6 studies reported the number of subjects tested for each cuff size. Details on the selection of cuff size, midarm circumference of the population and/or midarm circumference by cuff size used were scarcely reported.

Definition of diastolic blood pressure

Most of the included studies used K5 for the definition of diastolic BP, as it is suggested by BHS and AAMI protocols. Some studies didn’t report by which Korotkoff sound (K4 or K5) was diastolic BP defined. K4 was reported in four studies while one study reported both K4 and K5 for all participants (35). Five studies used ANSI/AAMI/ISO protocol but reported K5 (25, 26, 30, 31, 33).

Validation criteria

Validation criterion 1 was used in all studies. Results for children were reported together with those of older participants (adults) in the case of studies in the general population, and only one study (1 out of 13) reported data on criterion 1 separately for children (28).

Conclusion

The level of evidence-based upon pediatrics studies for the established validation criteria in children and adolescents needs to be assessed to evaluate the suitability of these criteria in children and adolescents. When evidence does not exist then extrapolation of data from adult studies is usually applied, but limitations of such strategy need to be acknowledged and gaps of evidence would serve as motivation for designing the new research activities. This is the case for BP measuring devices validation studies in children and adolescents. In addition, most validation studies analyzed children’s data along with adult ones posing significant uncertainty on the accuracy of the BP measuring validated devices in the pediatric population. Given that automated oscillometric BP devices become extensively popular in routine clinical practice for the diagnosis of high BP in childhood the need of validation protocols addressing the needs and special characteristics of children and adolescents is emerging to ensure accurate evaluation of BP levels in childhood.

Author’s note

This publication is based on the work of the COST Action HyperChildNET (CA19115).

Author contributions

SS an EL: conceptualization. SS, AC, KE, CS, CA, PP, JC, and GH: writing—original draft preparation. SS and AC: writing—review and editing. All authors have read and agreed to the current version of the manuscript.

Funding

This work was supported by COST (European Cooperation in Science and Technology), and the Horizon 2020 Framework Program of the European Union.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.1001878/full#supplementary-material

References

1. O’Brien E, Alpert BS, Stergiou GS. Accurate blood pressure measuring devices: influencing users in the 21st century. J Clin Hypertens. (2018) 20:1138–41. doi: 10.10111/jch.13278
2. American National Standards Institute, Association for the Advancement of Medical Instrumentation. ANSI/AAMI Sp10:1987, Electronic or Automated Sphygmomanometers. Arlington, VA: AAMI (1987).
3. O’Brien E, Petrie J, Littler W, de Swiet M, Padfield PL, O’Malley K, et al. The British hypertension society protocol for the evaluation of automated and semi-automated blood pressure measuring devices with special reference to ambulatory systems. J Hypertens. (1990) 8:607–19. doi: 10.1097/0004872-199007000-00004
4. O’Brien E, Petrie J, Littler WA, de Swiet M, Padfield PL, Altman D, et al. The British hypertension society protocol for the evaluation of blood pressure measuring devices. J Hypertens. (1995) 13:43–63.
5. Tholli U, Lieders S, Bramlage F, Dechend R, Eckert S, Mengden T, et al. The German hypertension league (deutsche hochdruckliga) quality seal protocol for blood pressure-measuring devices: 15-year experience and results from 105 devices for home blood pressure control. Blood Press Monit. (2016) 21:197–205. doi: 10.1097/MBP.0000000000000186
6. O’Brien E, Atkins N, Stergiou G, Karpettas N, Parati G, Asmar R, et al. European society of hypertension international protocol revision 2010 for the validation of blood pressure measuring devices in adults. Blood Press Monit. (2010) 15:23–38. doi: 10.1097/MBP.0b013e32836e0989
7. O’Brien E, Pickering T, Asmar R, Myers M, Parati G, Staessen J, et al. Working Group on blood pressure monitoring of the European society of hypertension international protocol for validation of blood pressure measuring devices in adults. Blood Press Monit. (2002) 7:3–17. doi: 10.1097/01.mbp.0000216097-200202000-00002
8. International Organization for Standardization. Noninvasive Sphygmomanometers: Clinical Validation of Automated Measurement Type. Geneva: International Organization for Standardization (2009).
9. ISO. Noninvasive Sphygmomanometers - Part 2: Clinical Investigation of Automated Measurement Type. New York, NY: American National Standards Institute (2013).
10. Stergiou GS, Alpert B, Mieke S, Asmar R, Atkins N, Eckert S, et al. A universal standard for the validation of blood pressure measuring devices: association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (Aami/Esh/Iso) Collaboration Statement. Hypertension. (2018) 71:368–74. doi: 10.1161/HYPERTENSIONAHA.117.102375
11. Stergiou GS, Boubouchiapoulou N, Kollias A. Accuracy of automated blood pressure measurement in children: evidence, issues, and perspectives. Hypertension. (2017) 69:1000–6. doi: 10.1161/HYPERTENSIONAHA.116.08553
12. Friedman BA, Alpert BS, Osborn D, Prisant LM, Quinn DE, Seller I. Assessment of the validation of blood pressure monitors: a statistical reappraisal. Blood Press Monit. (2008) 13:187–91. doi: 10.1097/MBP.0b013e3283071a64
13. Stabouli S. Office and out of office blood pressure measurements. In: Lurbe E, Wohl E editors. Hypertension in Children and Adolescents Updates in Hypertension and Cardiovascular Protection. Cham: Springer (2019). doi: 10.1007/978-3-030-18167-3_4
14. Butani L, Morgenstern RZ. Are pitfalls of oscillometric blood pressure measurements preventable in children? Pediatr Nephrol. (2003) 18:313–8. doi: 10.1007/s00467-003-1075-7
15. Nilsson PM, Lurbe E, Laurent S. The early life origins of vascular ageing and cardiovascular risk: the eva syndrome. J Hypertens. (2008) 26:1049–57. doi: 10.1097/HJH.0b013e3282823e
16. Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, et al. 2016 European society of hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. (2016) 34:1887–920. doi: 10.1097/hjha.0000000000001039
17. Addo OY, Himes JH, Zemel BS. Reference ranges for mid-upper arm circumference, upper arm muscle area, and upper arm fat area in Us children and adolescents Aged 1-20 Y. Am J Clin Nutr. (2017) 105:111–20. doi: 10.3945/ajcn.116.142190
18. Mramba L, Ngari M, Mwanongo M, Mwachia L, Bauni E, Walker AS, et al. A growth reference for mid upper arm circumference for age among school age children and adolescents, and validation for mortality: growth curve construction and longitudinal cohort study. BMJ. (2017) 358:j3423. doi: 10.1136/bmj.j3423
19. Flynn TJ, Kaebel DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. (2017) 140:e20171904. doi: 10.1542/peds.2017-1904
20. Stergiou GS, Alpert BS, Mieke S, Wang J, O’Brien E. Validation protocols for blood pressure measuring devices in the 21st century. J Clin Hypertens. (2018) 20:1096–9. doi: 10.1111/jch.13294
21. Mattu GS, Heran BS, Wright JM. Comparison of the automated non-invasive oscillometric blood pressure monitor (Bptrus) with the auscultatory mercury sphygmomanometer in a paediatric population. Blood Press Monit. (2004) 9:39–45. doi: 10.1097/00126997-200402000-00008
22. Lang SM, Giuliano JS Jr, Carroll CL, Rosenkrantz TS, Eisenfeld L. Neonatal/infant validation study of the cas model 740 noninvasive blood pressure monitor with the orion/maxiq nhrp module. Blood Press Monit. (2014) 19:180–2. doi: 10.1097.mbp.000000000000036
23. Wong SN, Tz Sang RY, Leung LC. Validation of three oscillometric blood pressure devices against auscultatory mercury sphygmomanometer in children. Blood Press Monit. (2006) 11:281–91. doi: 10.1097/01.mbp.0000209982.09623.34
24. Lee CG, Park HM, Shin HJ, Moon JS, Hong YM, Kim NS, et al. Validation study of the dinamap procare 200 upper arm blood pressure monitor in children and adolescents. Korean J Pediatr. (2011) 54:463–9. doi: 10.3345/kjp.2011.54.14.463
25. Dong J, Dong H, Yan Y, Xi B, Mi J. Validation of the raycome Rbp-1200 upper-arm pulse wave device in children aged 3-12 years according to the association for the advancement of medical instrumentation protocol. Blood Press Monit. (2017) 22:40–3. doi: 10.1097/mbp.0000000000000217
26. Zhang HJ, Zhang J, Wang SL, Zhang J, Teng LN, Zhang SJ, et al. Validation of the Yuwell Y900 oscillometric blood pressure monitor for professional office use in adults and children according to the Ami/Esh/Iso Universal Standard (Iso 80601-2:2018). Blood Press Monit. (2021) 26:396–9. doi: 10.1097/mbp.0000000000000541
27. Alpert BC. Validation of Cas Model 9010 automated blood pressure monitor: children/adult and neonatal studies. Blood Press Monit. (1996) 1:69–73.

28. Ling J, Ohara Y, Orime Y, Noone GP, Takatani S. Clinical evaluation of the oscillometric blood pressure monitor in adults and children based on the 1992 AAMI Sp-10 standards. J Clin Monit. (1995) 11:123–30. doi: 10.1007/bf01617734

29. Alpert BS, Blakely DW. Validation of the Fukuda Denshi Dr-7000/Nibp-701 patient monitor by Aami standard testing. Blood Press Monit. (2009) 14:274–6.

30. Kollias A, Nitineri A, Kyriakoulis KG, Stamboliu E, Lagou S, Boubouchiropoulou N, et al. Validation of the professional device for blood pressure measurement microdite watchbp office in adults and children according to the American National Standards Institute/Association for the Advancement of Medical Instrumentation/International Organization for Standardization Standard. Blood Press Monit. (2018) 23:112–4. doi: 10.1097/mbp.0000000000000307

31. Alpert BS. Validation of the step deflation algorithm of the midmark ipvitals zone vital signs monitor: part of a novel clinical ecosystem. Blood Press Monit. (2021) 26:234–6. doi: 10.1097/mbp.0000000000000524

32. Alpert BS. Validation of the Nihon Kohden Pvm-2701/impulse-1 automated device by both Aami (2002) and Iso standards testing. Blood Press Monit. (2012) 17:207–9. doi: 10.1097/MBP.0b013e32835c4b1e

33. Meng L, Zhao D, Pan Y, Ding W, Wei Q, Li H, et al. Validation of Omron Hbp-1300 professional blood pressure monitor based on auscultation in children and adults. BMC Cardiovasc Disord. (2016) 16:9. doi: 10.1186/s12872-015-0177-2

34. Saito K, Hirose Y, Takahashi H. Validation of the Omron Hbp-1320 for Professional Use According to the Aami/Aami/Iso 81060-2: 2013 protocol and the 2010 revision of the European society of hypertension international protocol. Blood Press Monit. (2020) 25:162–6. doi: 10.1097/mbp.0000000000000437

35. Chahine MN, Assemaani N, Sayed Hassan G, Cham M, Salameh P, Asmar R. Validation of the Omron M3500 blood pressure measuring device using normal- and high-speed modes in adult and specific populations (obese and children) according to AAMI protocol. J Clin Hypertens. (2015) 17:622–9. doi: 10.1111/jch.12540

36. Alpert BS. Validation of the Welch Allyn Pro Bp 2000, a professional-grade inflation based automated sphygmomanometer with arrhythmia detection in a combined pediatric and adult population by Aami/Iso standard testing. Blood Press Monit. (2018) 23:315–7. doi: 10.1097/mbp.0000000000000350

37. Alpert BS. Validation of the Welch Allyn Probp 3400: a device for modern medical practice. Blood Press Monit. (2011) 16:156–8. doi: 10.1097/MBP.0b013e328346d61b

38. Alpert BS. Validation of the Welch Allyn Surebp (Inflation) and Stepbp (Deflation) algorithms by aami standard testing and bhs data analysis. Blood Press Monit. (2011) 16:96–8. doi: 10.1097/MBP.0b013e328345232f

39. Alpert BS. Validation of the welch allyn spot vital signs blood pressure device according to the Aami/Aami Sp10: 2002. Accuracy and cost-efficiency successfully combined. Blood Press Monit. (2007) 12:345–7. doi: 10.1097/MBP.0b013e3282c9abf7